B+
Bull case
25%
Probability
Target price
$3.50
+95.5% vs current
ALLO
Allogene TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.90
+6.1% vs current
B-
Bear case
30%
Probability
Target price
$0.80
-55.3% vs current
AI sentiment snapshot
Latest data as of 2026-06-11
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.8
Score
AI commentary
News flow turned more constructive after the May 13 update because the AP snapshot flagged a small EPS beat and stored earnings context pointed to better-than-feared runway and encouraging early clinical signals. But the June 9 anchor price of $1.82 versus the roughly $2.33 level cited in immediate post-print coverage suggests the initial reaction faded, which fits a lower-conviction monitoring setup rather than a confirmed trend change. Social and options context are not provided in the packet, so confidence should stay anchored to company filings, stored earnings context, and milestone timing instead of secondary sentiment.
RankAlpha Sentiment Codex - 2026-06-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-13eventQ1 update and April financing eased the immediate balance-sheet overhangHigh impact
The May 13 Form 8-K says Allogene furnished a Q1 corporate update and financial-results press release, while stored earnings context reports $266.9 million of cash, cash equivalents and investments at March 31, 2026 and $200.4 million of April gross proceeds extending runway into Q1 2029. That reduces near-term financing pressure, but the rerating still needs clinical follow-through rather than balance-sheet relief alone [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
2026-11-15catalystALLO-329 autoimmune update is the next meaningful binary checkHigh impact
Stored earnings-call context says the Phase 1 RESOLUTION trial had treated nine patients across the first two dose levels, with early signs of clinical activity, favorable tolerability, ongoing dose escalation and lymphodepletion optimization, and a next update expected in Q4 2026. This is the clearest nearer-term program-specific de-risking event, but it remains early-stage and should be treated as a monitoring catalyst rather than confirmed efficacy proof [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
2027-06-30catalystALPHA3 mid-2027 EFS remains the real platform rerating testHigh impact
Stored earnings-call context says the ALPHA3 interim futility analysis showed 58.3% MRD clearance in the cema-cel arm versus 16.7% in observation and that the interim EFS analysis is expected in mid-2027. The early MRD and ctDNA read-through is supportive, but durable event-free-survival remains the main proof point for a larger platform rerating [#SEC-8K-2026-05-13][#PR-EARNINGS-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology